Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 701–800 of 963
Comparison of Reading Levels of Pharmacy Students and Reading Level of Primary Literature
Ficzere, C., Hagan, A. M., Ness, G. L., Greene, E., & Hill, K. (2016) · INNOVATIONS in pharmacy · doi:10.24926/iip.v7i3.448 · Cited by 3
Rautiainen, P., Tirkkonen, H., & Laatikainen, T. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0027 · Cited by 2
Hummel, M., & Achenbach, P. (2015) · Der Internist · doi:10.1007/s00108-014-3626-3 · Cited by 2
Insulin Resistance in Type 1 Diabetes: Evidence and New Insights
Filippo, P. D. (2018) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2018.06.555686 · Cited by 2
Stefan, N. (2020) · Diabetes Mellitus · doi:10.14341/dm10376 · Cited by 3
Reducing the Burden of Diabetes Mellitus in the State of Missouri: A Call to Action.
Drees, B. M., & Yun, S. (2016) · Europe PMC (PubMed Central) · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Kaza, M., Tsentidis, C., Vlachopapadopoulou, E. A., Karanasios, S., Sakou, I.-I., Paltoglou, G., Mastorakos, G. P., & Karavanaki, K. (2023) · Endocrine · doi:10.1007/s12020-023-03370-2 · Cited by 2
Takahashi, H., & Nishimura, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13363 · Cited by 1
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 4
Nylander, C. (2016) · Uppsala University Publications (Uppsala University) · Cited by 4
Drug delivery in the anterior chamber of the eye for islet transplantation as a diabetic treatment
Fan, Y. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/75793 · Cited by 2
Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J., & Li, W. (2021) · Research Square · doi:10.21203/rs.3.rs-961629/v1 · Cited by 2
Admission glucose as a prognostic marker for all-cause mortality and cardiovascular diseasePreprint
Djupsjö, C., Kuhl, J., Andersson, T., Lundbäck, M., Holzmann, M. J., & Nyström, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1715964/v1 · Cited by 2
HELMINTH INFECTIONS IN PREGNANCY : FROM MATERNAL-FETAL COMMITMENT TO TREATMENT
LOVISA, H., Spezia, J., & Anghebem-Oliveira, M. I. (2016) · Visão Acadêmica · doi:10.5380/acd.v17i1.46308 · Cited by 1
Kardiovaskuläres Risiko und chronische Entzündung
Milatz, F. (2019) · Kinder- und Jugendmedizin · doi:10.1055/a-1004-1802 · Cited by 1
Intrasplenic implantation of tissue-engineered pancreatic construct in experimental diabetic rats
Skaletskaya, G. N., Skaletskiy, N. N., Кирсанова, Л. А., Bubentsova, G. N., & Sevastianov, V. I. (2020) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2020-1-134-141 · Cited by 1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
Prattichizzo, F., & Ceriello, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00969-3 · Cited by 1
Clinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 3
Demographic Predictors of Elevated LDL Cholesterol in Type 1 Diabetes: A Cross-Sectional Study
Dart, M. E., Patrie, J. T., & Love, K. M. (2024) · Clinical Diabetes · doi:10.2337/cd24-0051 · Cited by 2
Lund, E., Vistisen, D., Svensson, J., Birkebaek, N., & Rønn, P. F. (2025) · Diabetic Medicine · doi:10.1111/dme.70055 · Cited by 1
Narum, M., Christensen, J. J., Holven, K. B., Berg, T. J., & Sveen, K. A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02844-z · Cited by 2
Ssemmondo, E., Newham, M., Deshmukh, H., Wilmot, E. G., Walton, C., Barnes, D., Ryder, R. E. J., & Sathyapalan, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70076 · Cited by 1
Liu, Z., Wang, K., Zeng, G., Pan, W., & Zhu, L. (2025) · Medicine · doi:10.1097/md.0000000000044419 · Cited by 1
Wang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Becker, M., Weiskorn, J., Wiegand, S., Röbl, M., Meißner, T., Schulz, E., Golembowski, S., Schwab, K. O., Meraner, D., & Holl, R. W. (2025) · Diabetes Care · doi:10.2337/dc25-1195 · Cited by 1
Honda, T., Henry, T. D., VanDerslice, J. A., Porucznik, C. A., Corlin, L., Gilani, O., Kirwa, K., Lázaro-Guevara, J. M., & Pezzolesi, M. G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112983 · Cited by 2
Sweeney, N. K., Atisha‐Fregoso, Y., Pozovskiy, R., Higdon, L. E., Anderson, M. S., Diamond, B., & Ridgway, W. M. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102684 · Cited by 1
“However, even with advances in glucose monitoring and administration of insulin, T1D patients are at elevated risk of hypoglycemia, DKA, and death due to poor glucose control [61].”
Horton, W. B., Mosslemi, M., Valenzuela, M. S., Miller, R. G., Orchard, T. J., & Costacou, T. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109235 · Cited by 1
Riasat, M. H., Nafees, S., Malik, S., Rahman, S., Lopez, K., Abdulhadi, O., Wright, N., Chikhal, R., & Benamer, S. (2025) · Cureus · doi:10.7759/cureus.98557 · Cited by 1
Bian, L., Yang, C., Jin, Y., Wang, H., Zhu, M., Xu, J., Bai, J., Zhang, M., Liu, Y., Yang, T., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341915 · Cited by 2
“The importance of glycemic control in preventing diabetic complications was initially demonstrated by the Diabetes Control and Complications Trial (DCCT), leading to a recommendation for individuals with T1D to achieve target HbA1c levels of 7.0% to minimize complication risk [4–7].”
InfluentialBergenstal, R. M., Willis, H. J., & Carlson, A. L. (2026) · Diabetes Care · doi:10.2337/dci26-0010 · Cited by 1
Beernink, J. M., Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Groop, P., Ji, L., Mathieu, C., Rosas, S. E., Tuttle, K. R., et al. (2026) · Diabetes Care · doi:10.2337/dc26-0882 · Cited by 1
Nielsen, L. B., Bartholdy, A., Nguyen, T., Jensen, M., Rasmussen, S., Guasch‐Ferré, M., & Merino, J. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101795 · Cited by 1
“First, as in other registry-based studies, 32,33 prescription redemption was used as a proxy for medication intake, which assumes that filled prescriptions reflect actual use.”
Gupta, L., Lal, P. R., Gupta, Y., Mani, K., Goyal, A., Sati, H. C., Seth, V., & Tandon, N. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103484 · Cited by 1
Was können Sensor, Pumpe, Bolusrechner?
Schlüter, S. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0589-y · Cited by 1
Excess mortality in well-controlled T1DM without renal disease
Karalliedde, J. J., & Viberti, G. C. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.249 · Cited by 2
Ranting in 2016: A Medical System in Crisis
Hirsch, I. B. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0435 · Cited by 1
Management of Overt Diabetic Kidney Disease and Uremia
Schernthaner, G., & Prischl, F. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-08873-0_5 · Cited by 1
Making a Difference With Diabetes Research and Care
Gerstein, H. C. (2016) · Diabetes Care · doi:10.2337/dci16-0016 · Cited by 2
HbA1c gut — Mortalität bei Typ-1-Diabetes normal
Jaursch-Hancke, C. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0921-1 · Cited by 1
Is atrial fibrillation another manifestation of organ damage in diabetes?
Miyazawa, K., & Lip, G. Y. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30282-6 · Cited by 1
Islet Cell or Pancreas Transplantation
Piemonti, L., Socci, C., Nano, R., Maffi, P., & Secchi, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_23 · Cited by 2
Heller, T., Kloos, C., Lehmann, T., Schiel, R., Lorkowski, S., Wolf, G., Müller, U. A., & Muller, N. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0044-102046 · Cited by 1
Deola, S., Guerrouahen, B. S., Sidahmed, H., Al-Mohannadi, A., Elnaggar, M., Elsadig, R., Abdelalim, E. M., Petrovski, G., Gadina, M., Thrasher, A. J., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1652-y · Cited by 2
Atherosclerosis and Diabetic Nephropathy
Duivenvoorden, R. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_22 · Cited by 3
Duration of Insulin Supply in Type 1 Diabetes: Are 90 Days Better or Worse Than 30 Days?
Rogers, M. A. M., Kim, C., Tipirneni, R., Basu, T., & Lee, J. M. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0054 · Cited by 1
Diabetic retinopathy and its’ association with carotid intima media thickness.
Bashir, F., Khan, B., & Tanveer, S. (2019) · The Professional Medical Journal · doi:10.29309/tpmj/2019.26.09.2040 · Cited by 1
Garavelli, S., Prattichizzo, F., Ceriello, A., Galgani, M., & de Candia, P. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0053 · Cited by 2
Clinical Translation of Porcine Islets for Treating Type 1 Diabetes
Aggarwal, S., Pepper, A., & Korbutt, G. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100354 · Cited by 1
Amor, A. J., Ortega, E., Giménez, M., Cofán, M., Blanco, J., Pané, A., Boswell, L., Vinagre, I., Esmatjes, E., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2019.09.001 · Cited by 1
Schwab, K. O., Doerfer, J., & Hanssen, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-52783-2_10 · Cited by 1
Ayanoğlu, M., Yiş, U., Tuhan, H., Polat, A., Okur, T. D., Edem, P., Paketçi, C., Bayram, E., Abacı, A., & Hız, S. (2022) · Neurology Asia · doi:10.54029/2022fxx · Cited by 1
Impact of overweight and obesity on epicardial adipose tissue in children with type 1 diabetes
Cielonko, L. A., Sabati, A. A., Chambers, M. A., Newbern, D., Swing, E. L., Chakravarthy, V., Mullen, J., Schmidt, J., Lutz, N., Shaibi, G. Q., et al. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0412 · Cited by 2
Anderson, M. A. B., & Stanger, C. (2023) · Children s Health Care · doi:10.1080/02739615.2023.2226393 · Cited by 3
Defining Outcomes for β-Cell Replacement Therapy
Rickels, M. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_65 · Cited by 1
Patient Selection: Pancreas or Islet Transplantation
Rao, S., Stumpf, M. M., & Brayman, K. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_18 · Cited by 2
Ólafsdóttir, A. F., & Lind, M. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1247616 · Cited by 1
“Good glycemic control is a key element in the reduction of long-term diabetes complications in people with type 1 diabetes (1).”
BackgroundSelf-citationFreitas, S. C. F., Dutra, M. R. H., Dourado, P. M. M., de Miranda, V. H. M., dos Santos, C. P., Sanches, Í. C., Irigoyen, M. C., & Angelis, K. D. (2024) · Pharmaceuticals · doi:10.3390/ph17050577 · Cited by 1
Research on the Influencing Factors that affecting Female Diabetes
Li, Y. (2024) · Highlights in Science Engineering and Technology · doi:10.54097/adfmaq54 · Cited by 4
Pakha, D. N., Yudhani, R. D., & Irham, L. M. (2024) · Genomics & Informatics · doi:10.1186/s44342-024-00005-4 · Cited by 2
Eken, B., Rawshani, A., Rawshani, A., Mandalenakis, Z., Thunström, E. Ö., Louca, A., Pétursson, P., Angerås, O., Nadhir, S., Dworeck, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080710 · Cited by 2
Bakhashab, S., Barber, R., O’Neill, J., Arden, C., & Weaver, J. U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158087 · Cited by 3
“Moreover, recent data estimated a standard CVD-related mortality ratio of 5.7 and 11.3 for men and women with T1DM, respectively [10], and revealed a 10-fold elevated risk of CVD-related mortality in T1DM individuals overall [11].”
BackgroundInfluentialRouland, A., Gautier, T., Denimal, D., Duvillard, L., Simoneau, I., Rageot, D., Vergès, B. L., & Bouillet, B. (2024) · Metabolites · doi:10.3390/metabo14090487 · Cited by 1
Role of lipopolysaccharide in genesis of microvascular complications in type 1 diabetes mellitus
Beloglazov, V. A., Yatskov, I. A., & Ulyanova, D. I. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-rol-2863 · Cited by 2
Barmpagianni, A., Karamanakos, G., Anastasiou, I. A., Kountouri, A., Lambadiari, V., & Liatis, S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108946 · Cited by 1
Hagelqvist, P. G., Andreasen, C. R., Maytham, K. B., Hamid, Y. H., Lindhardt, T. B., Hartmann, B., Knop, F. K., Andersen, A., & Vilsbøll, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16607 · Cited by 1
糖尿病合併症の実態とその抑制に関する大規模観察研究―1型糖尿病の登録時臨床像:JDCP study 2―
糖尿病データベース構築委員会, 理明, 西., 泉和生, 林野, 泰., 秀樹, 折., 光彦, 野., 浩二郎, 植., & 尚子, 田. (2015) · 糖尿病 · doi:10.11213/tonyobyo.58.426 · Cited by 1
Cetoacidosis diabética en niños: experiencia hospitalaria. Estudio retrospectivo de 15 años
Rivera, N. G., Zárate, M. G. G., Chon, I. F., Figueroa, C. O. G., Jiménez, I. A. G., & García, L. V. (2015) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2015.09.002 · Cited by 4
Childhood-onset Type 1 diabetes and cardiovascular disease
Perchard, R., & Amin, R. (2015) · Diabetes Management · doi:10.2217/dmt.14.61 · Cited by 1
Narendran, P. (2015) · Diabetes · doi:10.2337/db15-0825 · Cited by 1
Benefits of continuous subcutaneous insulin infusion in type 1 diabetes. Is there any doubt?
Martínez‐Brocca, M. A. (2016) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.11.018 · Cited by 1
Petersen, K. S., Keogh, J. B., Meikle, P. J., Garg, M. L., & Clifton, P. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i1.18 · Cited by 2
Martínez‐Brocca, M. A. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.11.006 · Cited by 1
Overweight and Obesity in Saudi Adults with Type 1 Diabetes Mellitus
Aljabri, K. S. (2018) · Archives of Diabetes & Obesity · doi:10.32474/ado.2018.01.000115 · Cited by 1
van der Heyden, J. C., Birnie, E., Bovenberg, S. A., Dekker, P., Veeze, H. J., Mul, D., & Aanstoot, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0950-9677 · Cited by 1
“Patients with type 1 diabetes (T1D) have an increased risk for premature cardiovascular disease (CVD) and cardiovascular mortality [1, 2].”
BackgroundMedical Specialty Camps: Camper/Staff Perceptions From the ACA Youth Outcomes Battery
Allen, A., Smith, E., & Hill, E. L. (2019) · Journal of Outdoor Recreation Education and Leadership · doi:10.18666/jorel-2019-v11-i3-9919 · Cited by 1
Rawshani, A., Rawshani, A., Sattar, N. A., Franzen, S., McGuire, D. K., Eliasson, B., Svensson, A., Zethelius, B., Miftaraj, M., Rosengren, A., et al. (2019) · Yearbook of pediatric endocrinology · doi:10.1530/ey.16.10.17 · Cited by 1
Self-citationDapagliflozin: an effective adjunctive treatment in type 1 diabetes
Yadegarfar, G., Livingston, M. A., Cortés, G., Alshames, R., Leivesley, K., Metters, A., Horne, L., Steele, T., & Heald, A. H. (2021) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000248 · Cited by 1
The Future of Clinical Islet Transplantation in the United States
Knoll, M. F., Knoll, C. A., Bottino, R., Bertera, S., & Trucco, M. (2021) · OBM Transplantation · doi:10.21926/obm.transplant.2101140 · Cited by 1
Costs and economic impacts of type-1 diabetes from the Dominican patient perspective
Martinez, A. G., Peña, C. N. V., Almonte, D. C., Castro, N. E. R., Colón-Arias, F., & Gresse, S. (2021) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2021.72.1 · Cited by 1
Early prediction of cardiovascular disease in patients with type 1 diabetes
Petrosyan, A., Diane, M., & Олеговна, К. Е. (2021) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2021-2-17-21 · Cited by 1
Islet Cell or Pancreas Transplantation
Piemonti, L., Socci, C., Nano, R., Maffi, P., & Secchi, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_23-1 · Cited by 2
Lablanche, S., Camille, L., & Benhamou, P. (2019) · Springer eBooks · doi:10.1007/978-3-319-98119-2_7 · Cited by 1
Alcohol, tobacco and the risk of LADA-latent autoimmune diabetes in adults
Rasouli, B. S. (2016) · Figshare · Cited by 2
Ambler, G. R., Cameron, F. J., Joshi, K., & Wherrett, D. K. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch15 · Cited by 1
Varkevisser, R. D. M., Mul, D., Aanstoot, H., Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2442331/v1 · Cited by 1
Can Islet Transplantation Possibly Reduce Mortality in Type 1 Diabetes
Isenberg, J. S., & KANDEEL, F. R. (2025) · Cell Transplantation · doi:10.1177/09636897241312801 · Cited by 1
Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease
Ahmed, S., Tirumalasetty, S., & Fonseca, V. A. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch13
Risiko für Mortalität und vaskuläre Ereignisse bei Frauen und Männern mit Typ-1-Diabetes
Jecht, M. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1349-2
E-health: wat wordt/is de toekomst bij de behandeling van diabetes?
Veeze, H. J., & Aanstoot, H. (2015) · Tijdschrift voor kindergeneeskunde · doi:10.1007/s12456-015-0010-8
Technical challenges in human islet isolation
Ståhle, M. (2015) · Uppsala University Publications (Uppsala University)
Glomerulopatías secundarias a enfermedades metabólicas, hematológicas y conectivopatías
Gutiérrez, E., Muñoz, M. T., Sevillano, Á., Auñón, P., & Hernández, E. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.06.013
Stark erhöhtes Mortalitätsrisiko selbst bei gut kontrolliertem HbA1C
Schloot, N. C. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0510-8
Typ-1-Diabetes auch bei gutem HbA1C gefährlich
Füeßl, H. S. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2578-4
Risiko für Mortalität und vaskuläre Ereignisse bei Frauen und Männern mit Typ-1-Diabetes
Jecht, M. (2015) · Der Urologe · doi:10.1007/s00120-015-3851-y
Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1409-7
From THE INSTITUTE OF ENVIRONMENTAL MEDICINE
Giuseppe, D. D. (2014)
L’eccesso di mortalità nelle persone con diabete di tipo 2
Bonadonna, R. C. (2016) · L Endocrinologo · doi:10.1007/s40619-016-0175-0
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.